Immunitrack’s NeoScreen platform can help your company to identify MHC-restricted CD4 or CD8 epitopes from any cancer, biotherapeutic, viral or bacterial pathogen, fast and with unmatched precision.
Figure 1. Typical NeoScreen workflow. A. Client provides us with the sequence of their biotherapeutic or the sequence of their viral, bacterial or neo-antigen. B. We will help you assess, design and produce the peptides you wish to analyse. These peptides are subsequently screened with MHC molecules of interest (see list of available MHC alleles here). C. Using our NeoScreen platform, we will assess which epitopes bind the chosen MHC molecules, and identify those most likely to elicit a T cell response. D. We then produce a report which contains the raw data from the analysis conducted. E. Data may be applied for drug development e.g. vaccine optimisation or drug safety assessment. F. We can produce the MHC/epitope pairs that form stable interactions so that our client can carry out further investigations at their own facilities. G. Flow cytometry studies may be performed using our MHC monomer and tetramers.
Next generation sequencing of tumour biopsies allows personalised identification of neo-epitopes (cancer-specific mutations). This information may reveal cancer-specific epitopes and can be used in many applications, including:
Immunitrack’s NeoScreen platform technology supports early stage immunotherapy development including personalised cancer vaccines and T-cell therapies.
NeoScreen facilitates rapid high-throughput screening of major histocompatibility complex class I and II (MHC I & II) interactions with neo-epitopes to identify candidate epitopes for further development.
Contact us by email at info@immunitrack.com, by phone using the numbers listed below, or use our online contact form ▸
Tel. +45 2868 2159
